Approach to the Treatment-Experienced Patient

Infectious Disease Clinics of North America

Volumn 21, Issue 1, 2007, Pages 85-102

  Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

BRAIN HEMORRHAGE; CD4 LYMPHOCYTE COUNT; DRUG ACTIVITY; DRUG ADSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IC 50; LIVER TOXICITY; MENTAL DISEASE; MONOTHERAPY; PATIENT COMPLIANCE; REVIEW; SUBSTANCE ABUSE; TREATMENT FAILURE; VIREMIA; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; TREATMENT FAILURE;

EID: 34248327454     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.01.003     Document Type: Review

References (71)

1. Deeks S.G., Hecht F.M., Swanson M., et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13 (1999) F35-F43
2. Ledergerber B., Egger M., Opravil M., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV cohort study. Lancet 353 (1999) 863-868
3. Mocroft A., Phillips A.N., Miller V., et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS 15 (2001) 201-209
4. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, October 10, 2006. Available at: http://www.aidsinfo.nih.gov. Accessed November 4, 2006.
5. DeJesus E., Herrera G., Teofilo E., et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39 (2004) 1038-1046
6. Barreiro P., and Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 58 (2006) 220-221
7. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142 [Abstract THLB0204]. Presented at the XVI International AIDS Conference. Toronto (Canada), August 13-18, 2006.
8. Moore RD, Keruly JC. Changes in CD4 count out to six years in persons with sustained virologic suppression. Implications for when to startARV therapy? [Abstract THPE0109]. Presented at the XVI International AIDS Conference. Toronto (Canada), August 13-18, 2006.
9. King M, Da Silva BA, McMillan F, et al. When does the CD4 cell count plateau? Evidence from subjects treated with a lopinavir/ritonavir-based regimen for up to 7 years. [Abstract H-1401]. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 27-30, 2006.
10. Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 (2006) 827-843
11. Havlir D.V., Bassett R., Levitan D., et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286 (2001) 171-179
12. Nettles R.E., Kieffer T.L., Kwon P., et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 293 (2005) 817-829
13. Cohen Stuart J.W., Wensing A.M., Kovacs C., et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 28 (2001) 105-113
14. Martinez-Picado J., DePasquale M.P., Kartsonis N., et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A 97 (2000) 10948-10953
15. Podsadecki TJ, Vrijens B, Tousset E, et al. Lower adherence to HAART observed prior to transient HIV-1 viremia ("blips") [Abstract H-992]. Presented at the 46th ICAAC. San Francisco, September 27-30, 2006.
16. Hermankova M., Ray S.C., Ruff C., et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 286 (2001) 196-207
17. Stosor V., Palella Jr. F.J., Berzins B., et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis 41 (2005) 1671-1674
18. Kempf D.J., Rode R.A., Xu Y., et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12 (1998) F9-F14
19. Pilcher C.D., Miller W.C., Beatty Z.A., et al. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS 13 (1999) 1337-1342
20. Raboud J.M., Rae S., Hogg R.S., et al. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J Infect Dis 180 (1999) 1347-1350
21. Nettles R.E., Kieffer T.L., Simmons R.P., et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 39 (2004) 1030-1037
22. Napravnik S., Edwards D., Stewart P., et al. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 40 (2005) 34-40
23. Easterbrook P.J., Ives N., Waters A., et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/ml. AIDS 16 (2002) 1521-1527
24. Hatano H., Hunt P., Weidler J., et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 43 (2006) 1329-1336
25. Aleman S., Soderbarg K., Visco-Comandini U., et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16 (2002) 1039-1044
26. Lanier R., Scott J., Steel H., et al. Multivariate analysis of predictors of response to abacavir: comparison of prior antiretroviral therapy, baseline HIV RNA, CD4 count and viral resistance. [abstract 82]. Antivir Ther 4 Suppl 1 (1999) 56
27. Schooley R.T., Ruane P., Myers R.A., et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16 (2002) 1257-1263
28. Shulman N., Zolopa A., Havlir D., et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 46 (2002) 3907-3916
29. Descamps D., Flandre P., Calvez V., et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege Study Team. JAMA 283 (2000) 205-211
30. Gallego O., de Mendoza C., Perez-Elias M.J., et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 15 (2001) 1701-1706
31. Havlir D.V., Hellmann N.S., Petropoulos C.J., et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 283 (2000) 229-234
32. Maguire M., Gartland M., Moore S., et al. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 14 (2000) 1195-1201
33. Mouroux M., Yvon-Groussin A., Peytavin G., et al. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. J Clin Microbiol 38 (2000) 2726-2730
34. Baxter J.D., Mayers D.L., Wentworth D.N., et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14 (2000) F83-F93
35. Cingolani A., Antinori A., Rizzo M.G., et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 16 (2002) 369-379
36. Cohen C.J., Hunt S., Sension M., et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16 (2002) 579-588
37. Durant J., Clevenbergh P., Halfon P., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353 (1999) 2195-2199
38. Haubrich R., Keiser P., Kemper C., et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir Ther 6 (2001) 63
39. Meynard J.L., Vray M., Morand-Joubert L., et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16 (2002) 727-736
40. Tural C., Ruiz L., Holtzer C., et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16 (2002) 209-218
41. Lalezari J.P., Henry K., O'Hearn M., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348 (2003) 2175-2185
42. Lazzarin A., Clotet B., Cooper D., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348 (2003) 2186-2195
43. British HIV Association. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy, 2005. Available at: http://www.bhiva.org. Accessed November 24, 2006.
44. Gallant J.E., DeJesus E., Arribas J.R., et al. Tenofovir, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006) 251-260
45. Cohen C, Steinhart CR, Ward DJ, et al. Efficacy and safety results with the novel NNRTI, TMC 125, and impact of baseline resistance on the virologic response in study TMC125-C223 [Abstract TUPE0061]. Presented at the XVI International AIDS Conference. Toronto (Canada), August 13-18, 2006.
46. Colonno R., Rose R., McLaren C., et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 189 (2004) 1802-1810
47. Hertogs K., Bloor S., Kemp S.D., et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14 (2000) 1203-1210
48. Kempf D.J., King M.S., Bernstein B., et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 189 (2004) 51-60
49. MacManus S., Yates P.J., Elston R.C., et al. GW433908/ritonavir once daily in antiretroviral therapy naive patients: absence of protease inhibitor resistance at 48 weeks. AIDS 18 (2004) 651-655
50. Hicks C.B., Cahn P., Cooper D.A., et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368 (2006) 466-475
51. Cooper D, Hicks C, Lazzarin A, et al. 24-week RESIST study analyses: the efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ritonavir LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) [Abstract 560]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston (MA), February 22-25, 2005.
52. Lazzarin A, Queiros-Telles F, Frank I, et al. TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined 48 week analysis [Abstract TUAB0104]. Presented at the XVI International AIDS Conference. Toronto (Canada), August 13-18, 2006.
53. De Meyer S, Azijn H, Fransen E, et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors [Abstract 19]. Presented at the XV International HIV Drug Resistance Workshop. Sitges (Spain), June 13-17, 2006.
54. Deeks S.G., Wrin T., Liegler T., et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344 (2001) 472-480
55. Grabar S., Le Moing V., Goujard C., et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133 (2000) 401-410
56. Piketty C., Weiss L., Thomas F., et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 183 (2001) 1328-1335
57. Morse C, Maldarelli F, Dewar R, et al. Limited evolution of drug resistance in HIV-1-infected patients with persistent low-level viremia on a stable antiretroviral regimen for longer than 1 year [Abstract 678]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston (MA), February 22-25, 2005.
58. Eron J.J., Benoit S.L., Jemsek J.J., et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 333 (1995) 1662-1669
59. Catucci M., Venturi G., Romano L., et al. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. J Acquir Immune Defic Syndr 21 (1999) 203-208
60. Miller V., Cozzi-Lepri A., Hertogs K., et al. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther 5 (2000) 49-55
61. Montaner J.S., Harrigan P.R., Jahnke N., et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 15 (2001) 61-69
62. Katlama C., Dominguez S., Gourlain K., et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18 (2004) 217-226
63. Ruiz L., Ribera E., Bonjoch A., et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene study. J Infect Dis 188 (2003) 977-985
64. Delaugerre C., Valantin M.A., Mouroux M., et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 15 (2001) 2189-2191
65. Walmsley S, LaPierre N, Loutfy M, et al. CTN 164: A prospective randomized trial of structured treatment interruption vs immediate switching in HIV-infected patients experiencing virologic failure on HAART [Abstract 580]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston (MA), February 22-25, 2005.
66. Lawrence J., Mayers D.L., Hullsiek K.H., et al. Structured treatment interruption in patients with multi-drug resistant human immunodeficiency virus. N Engl J Med 349 (2003) 837-846
67. Deeks S.G., Hoh R., Neilands T.B., et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 192 (2005) 1537-1544
68. Castagna A., Danise A., Menzo S., et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 20 (2006) 795-803
69. Grinsztejn B, Nguyen BY, Katlama C, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [Abstract 159LB]. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver (CO), February 5-8, 2006.
70. Lu J., Deeks S.G., Hoh R., et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43 (2006) 60-64
71. Deeks S.G., Lu J., Hoh R., et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 195 (2007) 387-391